The Figlin Regime
Well, Karl is undergoing an IL-2 (Interluekin) regime from Dr.Robert Figlin from UCLA. He's had great success with melanoma and prostate Cancer patients with this treatment.
here's a link to the site for more details http://http://www.proleukin.com/patient_resources/melanoma/met_mel.aspx
The United States Food and Drug Administration (FDA) has approved two therapies for patients with metastatic melanoma, PROLEUKIN® IL-2 and dacarbazine.
PROLEUKIN IL-2, an immunotherapy agent, is approved by the FDA as a first choice in treatment for appropriate patients with metastatic melanoma. In the metastatic melanoma studies, objective responses were seen in 16% of patients. This included a 100% reduction of all tumor(s) in approximately 6% of patients and greater than 50% reduction in tumor(s) size in approximately 10% of patients. Unlike conventional therapies, immunotherapy drugs activate the body's own immune system to fight cancer. PROLEUKIN IL-2 gives patients a chance for a complete and long-lasting remission.
here's a link to the site for more details http://http://www.proleukin.com/patient_resources/melanoma/met_mel.aspx
The United States Food and Drug Administration (FDA) has approved two therapies for patients with metastatic melanoma, PROLEUKIN® IL-2 and dacarbazine.
PROLEUKIN IL-2, an immunotherapy agent, is approved by the FDA as a first choice in treatment for appropriate patients with metastatic melanoma. In the metastatic melanoma studies, objective responses were seen in 16% of patients. This included a 100% reduction of all tumor(s) in approximately 6% of patients and greater than 50% reduction in tumor(s) size in approximately 10% of patients. Unlike conventional therapies, immunotherapy drugs activate the body's own immune system to fight cancer. PROLEUKIN IL-2 gives patients a chance for a complete and long-lasting remission.
posted by LivingStrong at
7:51 AM
0 Comments:
Post a Comment
<< Home